Vaccinex, Inc. (VCNX)
OTCMKTS
· Delayed Price · Currency is USD
1.060
-0.020 (-1.85%)
Jan 21, 2025, 4:00 PM EST
Vaccinex Employees
As of December 31, 2023, Vaccinex had 40 total employees, including 37 full-time and 3 part-time employees. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
$9,949
Profits / Employee
-$476,333
Market Cap
2.84M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 2,931 |
Elite Pharmaceuticals | 64 |
Glass House Brands | 413 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 109 |
SANUWAVE Health | 31 |
Vaccinex News
- 5 weeks ago - Vaccinex Faces Nasdaq Delisting: What's Going On With The Stock? - Benzinga
- 2 months ago - Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC - GlobeNewsWire
- 2 months ago - Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - GlobeNewsWire
- 2 months ago - Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain - GlobeNewsWire
- 4 months ago - Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds - GlobeNewsWire
- 5 months ago - Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer's Disease and Plans to Pursue a Development Partnership - GlobeNewsWire
- 6 months ago - Vaccinex stock tanks 40% despite positive Alzheimer's study update - Invezz